EADV 2026

WATERTOWN, Mass., Sept. 1, 2026 Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class...

WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...